Hepion
HEPA

股本结构

单位：万股
公告日期 2025-04-28 2025-04-08 2025-03-14 2025-03-14 2025-03-04 2025-02-07
证券总股本 1092.73 1097.53 108.00 5425.00 3465.07 695.85
普通股本 1092.73 1097.53 108.00 5425.00 3465.07 695.85
优先股 8.56 未披露 未披露 未披露 未披露 8.56
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-04-24 2025-04-08 2025-03-18 2025-03-14 2025-01-31 2025-01-17
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-04-28 1092.73 8.56 定期报告 2025-04-24
2025-04-08 1097.53 未披露 定期报告 2025-04-08
2025-03-14 108.00 未披露
更多>>
1-for-50 reverse split of the issued shares of its common stock
2025-03-18
2025-03-14 5425.00 未披露 定期报告 2025-03-14
2025-03-04 3465.07 未披露 定期报告 2025-01-31
2025-02-07 695.85 8.56 定期报告 2025-01-17
2024-11-14 695.84 8.73
更多>>
From June 30, 2024 to September 30, 2024 Issuance of common stock
2024-09-30
2024-08-13 579.91 8.73
更多>>
From March 31, 2024 to June 30, 2024 Issuance of shares in abeyance
2024-06-30
2024-05-21 547.31 8.73
更多>>
From December 31, 2023 to March 31, 2024 Warrant exercises, net
2024-03-31
2024-04-16 547.25 未披露 定期报告 2024-03-13
2024-04-16 481.87 8.73
更多>>
From December 31,2022 to December 31,2023 Issuance of common stock in connection with stock split Issuance of common stock, net Warrant exercises
2023-12-31
2023-11-20 433.77 未披露 定期报告 2023-11-06
2023-10-02 423.83 8.74
更多>>
common stock offered 400,000 shares by the company
2023-10-03
2023-08-14 383.83 8.74
更多>>
From March 31, 2023 to June 30, 2023 Issuance of common stock in connection with stock split
2023-06-30
2023-05-10 381.15 未披露
更多>>
Hepion Pharmaceuticals, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, 2023.
2023-05-11
2023-04-28 7622.96 8.56 定期报告 2023-04-27
2023-04-10 7622.96 未披露 定期报告 2023-03-23
2023-04-10 7622.96 8.74
更多>>
From December 31, 2021 to December 31, 2022 Conversion of preferred stock to common Issuance of common stock for milestone payment
2022-12-31
2022-11-21 7622.96 208.56 定期报告 2022-11-08
2022-05-16 7622.96 8.74
更多>>
From December 31, 2021 to March 31, 2022 Conversion of Series C to common Issuance of common stock, net
2022-03-31
2022-04-08 7622.96 未披露 定期报告 2022-03-30
2021-11-15 7622.53 8.74
更多>>
From June 30, 2021 to September 30, 2021 Conversion of preferred stock to common Accretion of discount - preferred stock conversion
2021-09-30
2021-09-07 7622.84 8.56 定期报告 2021-08-23
2021-08-16 7622.52 8.74 定期报告 2021-06-30
2021-05-14 7622.52 未披露 定期报告 2021-05-07
2021-05-12 7622.84 8.56 定期报告 2021-04-29
2021-05-14 7622.52 8.74
更多>>
From December 31, 2020 To March 31, 2021 Conversion of preferred stock to common Accretion of discount Issuance of common stock, net
2021-03-31
2021-03-31 7622.52 未披露 定期报告 2021-03-24
2021-04-28 3202.52 未披露 定期报告 2021-02-28
2021-02-18 7622.52 未披露
更多>>
1.Common stock offered by the company 44,200,000 shares. 2.Based on 9,025,153 shares of common stock outstanding as of September 30, 2020, plus 23,000,000 shares issued during offering on November 25, 2020.
2021-02-18
2021-03-31 3202.52 8.74
更多>>
From December 31, 2019 to December 31, 2020 Conversion of preferred stock to common Issuance of common stock, net Warrant exercises
2020-12-31
2020-11-30 3202.52 未披露
更多>>
1.Common stock offered 20,000,000 shares of common stock. 2.Based on 9,025,153 shares of common stock outstanding as of September 30, 2020. 3.The Company has also granted the Representative a 45-day option to purchase up to 3,000,000 additional shares of common stock to cover over-allotments. On November 25, 2020, the Representative exercised the over-allotment in full.
2020-11-30
2020-11-27 1202.52 未披露
更多>>
The Company has also granted the Representative a 45-day option to purchase up to 3,000,000 additional shares of common stock to cover over-allotments. On November 25, 2020, the Representative exercised the over-allotment in full.
2020-11-25
2020-11-16 902.52 8.74
更多>>
From June 30, 2020 to September 30, 2020 Conversion of preferred stock to common Accretion of discount
2020-09-30
2020-08-12 902.52 未披露 定期报告 2020-08-05
2020-08-12 902.51 8.74
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock, net
2020-06-30
2020-06-15 902.51 未披露 定期报告 2020-05-11
2020-06-29 607.41 8.74
更多>>
From December 31, 2019 to March 31, 2020 Issuance of common stock, net Warrant exercises
2020-03-31
2020-03-27 607.41 未披露 定期报告 2020-03-25
2020-05-14 376.03 8.74
更多>>
From December 31, 2018 to December 31, 2019 Issuance of common stock, private placement Issuance of common stock, debt redemption Issuance of common stock, net Issuance of preferred stock, net Conversion of preferred stock Exercise of warrants
2019-12-31
2019-11-14 345.38 8.74
更多>>
From June 30, 2019 to September 30, 2019 Conversion of preferred stock Accretion of preferred stock discount upon conversion
2019-09-30
2019-08-14 345.36 8.74
更多>>
From April 1, 2019 to June 30, 2019 Accretion of preferred stock discount upon conversion Conversion of preferred stock Issuance of Preferred Stock Offering cost related to issuance of preferred stock Placement agent warrants Beneficial conversion feature of preferred stock Accretion of beneficial conversion feature of preferred stock Issuance of common stock, Debt Redemption Exercise of warrants
2019-06-30
2019-06-20 340.28 未披露 定期报告 2019-06-20
2019-06-19 80.28 未披露 定期报告 2019-06-17
2019-05-31 59.05 未披露
更多>>
On May 28, 2019, ContraVir Pharmaceuticals, Inc. (the “Company”) filed an amendment (the “Amendment”) to its certificate of incorporation, as amended, to effectuate a reverse stock split of the Company’s common stock, par value $0.0001 per share. Pursuant to the reverse stock split, at the effective time of 12:01 a.m. on May 31, 2019, each seventy (70) shares of common stock issued and outstanding were combined into one (1) validly issued, fully paid and non-assessable share of common stock (the “Reverse Stock Split”). As a result of the reverse split, each seventy pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 41.3 million shares to approximately 590,500 shares.
2019-06-03
2019-05-15 4133.39 未披露 定期报告 2019-05-10
2019-04-29 3444.18 未披露 定期报告 2019-04-29
2019-05-15 2079.00 8.75
更多>>
from January 1, 2019 to March 31, 2019 Issuance of common stock, Private Placement Issuance of common stock, Debt Redemption Conversion of Series C Preferred stock
2019-03-31
2019-04-02 2049.93 未披露 定期报告 2019-03-15
2019-03-14 1717.93 未披露 定期报告 2019-03-12
2019-03-14 1660.85 8.76
更多>>
from December 31, 2017 to December 31, 2018 Issuance of common stock, net Issuance of Series C Preferred Conversion of Series A Preferred Conversion of Series C Preferred Exercise of warrants
2018-12-31
2018-11-29 1634.39 8.56 定期报告 2018-11-28
2018-11-14 1634.39 未披露 定期报告 2018-11-12
2018-11-14 1631.51 8.78
更多>>
from December 31, 2017 to September 30, 2018 Conversion of Series A Preferred stock to common stock Issuance of Series C Preferred stock Conversion of Series C Preferred stock to common stock
2018-09-30
2018-08-14 1445.19 未披露 定期报告 2018-08-09
2018-08-14 1069.22 8.56
更多>>
from December 31, 2017 to June 30, 2018 Conversion of preferred stock to common stock Issuance of common stock, net
2018-06-30
2018-06-13 1068.68 未披露
更多>>
As a result of the reverse split, each 8 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 85.5 million shares to approximately 10.7 million shares. Proportionate adjustments will be made to the conversion and exercise prices of the company's outstanding warrants, stock options and to the number of shares issued and issuable under the company's equity incentive plans. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock.
2018-05-29
2018-05-15 8545.13 未披露 定期报告 2018-05-15
2018-05-15 8495.12 10.40
更多>>
From January 1, 2018 to March 31, 2018 Issuance of common stock, net
2018-03-31
2018-03-26 8495.12 未披露 定期报告 2018-03-16
2018-02-02 7885.09 10.40 定期报告 2018-01-23
2018-03-26 7834.00 10.40
更多>>
from June 30, 2017 to December 31, 2017 Issuance of common stock, net
2017-12-31
2017-10-27 7827.83 未披露 定期报告 2017-10-27
2017-11-14 7816.97 10.40
更多>>
From July 1, 2017 To September 30, 2017 Issuance of common stock, net
2017-09-30
2017-09-28 7800.18 未披露 定期报告 2017-09-15
2017-09-28 7570.73 10.40
更多>>
From June 30, 2016 to June 30, 2017 Issuance of common stock, net Conversion of preferred stock Warrant exercise Stock option exercise
2017-06-30
2017-04-12 6370.73 10.40
更多>>
From June 30, 2016 to March 31, 2017 Conversion of preferred stock to common stock Issuance of common stock, net Exercise of warrants Exercise of stock options
2017-03-31
2017-02-14 6277.97 12.31
更多>>
From June 30, 2016 to December 31, 2016 Issuance of common stock, net Conversion of preferred stock to common stock Exercise of warrants Exercise of stock options
2016-12-31
2016-11-14 5994.49 未披露 定期报告 2016-11-14
2016-10-28 6274.00 未披露
更多>>
3,468,454 shares of common stock issuable upon conversion of the Series A Preferred Stock
2016-10-28
2016-11-14 5559.19 18.31
更多>>
From June 30, 2016 to September 30, 2016 Issuance of common stock, net Conversion of preferred stock to common stock Stock option exercise
2016-09-30
2016-09-28 5365.57 未披露
更多>>
On June 10, 2016, we completed an acquisition of Ciclofilin Pharmaceuticals, Inc., a Delaware corporation (“Ciclofilin”), in accordance with certain Agreement and Plan of Merger dated May 26, 2016.At the closing of the Merger we acquired all of the outstanding equity interests in Ciclofilin in exchange for Ciclofilin having the right to receive future milestone payments.
2016-09-26
2016-09-28 3223.12 137.00
更多>>
From June 30, 2015 to June 30, 2016 Issuance of common stock, net Stock option exercise
2016-06-30
2016-05-13 3223.12 未披露 定期报告 2016-05-03
2016-05-13 2730.17 137.00
更多>>
from June 30, 2015 to March 31, 2016 Exercise of stock options Issuance of common stock, net
2016-03-31
2016-02-12 2729.51 137.00
更多>>
From June 30, 2015 to December 31, 2015 Exercise of stock options Issuance of common stock, net
2015-12-31
2015-11-12 2729.51 未披露 定期报告 2015-11-09
2015-11-12 2229.51 137.00
更多>>
from June 30, 2015 to September 30, 2015 Exercise of stock options
2015-09-30
2015-09-25 2229.51 未披露 定期报告 2015-09-17
2015-09-25 2227.67 137.00
更多>>
from June 30, 2014 to June 30, 2015 Issuance of series A preferred shares Issuance of series B preferred shares Restricted common shares issued in exchange of warrants Beneficial conversion feature accreted as a deemed dividend
2015-06-30
2015-03-09 2227.34 137.00 定期报告 2015-03-09
2015-02-27 2227.34 未披露 定期报告 2015-02-27
1-for-50 reverse split of the issued shares of its common stock
From June 30, 2024 to September 30, 2024 Issuance of common stock
From March 31, 2024 to June 30, 2024 Issuance of shares in abeyance
From December 31, 2023 to March 31, 2024 Warrant exercises, net
From December 31,2022 to December 31,2023 Issuance of common stock in connection with stock split Issuance of common stock, net Warrant exercises
common stock offered 400,000 shares by the company
From March 31, 2023 to June 30, 2023 Issuance of common stock in connection with stock split
Hepion Pharmaceuticals, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, 2023.
From December 31, 2021 to December 31, 2022 Conversion of preferred stock to common Issuance of common stock for milestone payment
From December 31, 2021 to March 31, 2022 Conversion of Series C to common Issuance of common stock, net
From June 30, 2021 to September 30, 2021 Conversion of preferred stock to common Accretion of discount - preferred stock conversion
From December 31, 2020 To March 31, 2021 Conversion of preferred stock to common Accretion of discount Issuance of common stock, net
1.Common stock offered by the company 44,200,000 shares. 2.Based on 9,025,153 shares of common stock outstanding as of September 30, 2020, plus 23,000,000 shares issued during offering on November 25, 2020.
From December 31, 2019 to December 31, 2020 Conversion of preferred stock to common Issuance of common stock, net Warrant exercises
1.Common stock offered 20,000,000 shares of common stock. 2.Based on 9,025,153 shares of common stock outstanding as of September 30, 2020. 3.The Company has also granted the Representative a 45-day option to purchase up to 3,000,000 additional shares of common stock to cover over-allotments. On November 25, 2020, the Representative exercised the over-allotment in full.
The Company has also granted the Representative a 45-day option to purchase up to 3,000,000 additional shares of common stock to cover over-allotments. On November 25, 2020, the Representative exercised the over-allotment in full.
From June 30, 2020 to September 30, 2020 Conversion of preferred stock to common Accretion of discount
From March 31, 2020 to June 30, 2020 Issuance of common stock, net
From December 31, 2019 to March 31, 2020 Issuance of common stock, net Warrant exercises
From December 31, 2018 to December 31, 2019 Issuance of common stock, private placement Issuance of common stock, debt redemption Issuance of common stock, net Issuance of preferred stock, net Conversion of preferred stock Exercise of warrants
From June 30, 2019 to September 30, 2019 Conversion of preferred stock Accretion of preferred stock discount upon conversion
From April 1, 2019 to June 30, 2019 Accretion of preferred stock discount upon conversion Conversion of preferred stock Issuance of Preferred Stock Offering cost related to issuance of preferred stock Placement agent warrants Beneficial conversion feature of preferred stock Accretion of beneficial conversion feature of preferred stock Issuance of common stock, Debt Redemption Exercise of warrants
On May 28, 2019, ContraVir Pharmaceuticals, Inc. (the “Company”) filed an amendment (the “Amendment”) to its certificate of incorporation, as amended, to effectuate a reverse stock split of the Company’s common stock, par value $0.0001 per share. Pursuant to the reverse stock split, at the effective time of 12:01 a.m. on May 31, 2019, each seventy (70) shares of common stock issued and outstanding were combined into one (1) validly issued, fully paid and non-assessable share of common stock (the “Reverse Stock Split”). As a result of the reverse split, each seventy pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 41.3 million shares to approximately 590,500 shares.
from January 1, 2019 to March 31, 2019 Issuance of common stock, Private Placement Issuance of common stock, Debt Redemption Conversion of Series C Preferred stock
from December 31, 2017 to December 31, 2018 Issuance of common stock, net Issuance of Series C Preferred Conversion of Series A Preferred Conversion of Series C Preferred Exercise of warrants
from December 31, 2017 to September 30, 2018 Conversion of Series A Preferred stock to common stock Issuance of Series C Preferred stock Conversion of Series C Preferred stock to common stock
from December 31, 2017 to June 30, 2018 Conversion of preferred stock to common stock Issuance of common stock, net
As a result of the reverse split, each 8 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 85.5 million shares to approximately 10.7 million shares. Proportionate adjustments will be made to the conversion and exercise prices of the company's outstanding warrants, stock options and to the number of shares issued and issuable under the company's equity incentive plans. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock.
From January 1, 2018 to March 31, 2018 Issuance of common stock, net
from June 30, 2017 to December 31, 2017 Issuance of common stock, net
From July 1, 2017 To September 30, 2017 Issuance of common stock, net
From June 30, 2016 to June 30, 2017 Issuance of common stock, net Conversion of preferred stock Warrant exercise Stock option exercise
From June 30, 2016 to March 31, 2017 Conversion of preferred stock to common stock Issuance of common stock, net Exercise of warrants Exercise of stock options
From June 30, 2016 to December 31, 2016 Issuance of common stock, net Conversion of preferred stock to common stock Exercise of warrants Exercise of stock options
3,468,454 shares of common stock issuable upon conversion of the Series A Preferred Stock
From June 30, 2016 to September 30, 2016 Issuance of common stock, net Conversion of preferred stock to common stock Stock option exercise
On June 10, 2016, we completed an acquisition of Ciclofilin Pharmaceuticals, Inc., a Delaware corporation (“Ciclofilin”), in accordance with certain Agreement and Plan of Merger dated May 26, 2016.At the closing of the Merger we acquired all of the outstanding equity interests in Ciclofilin in exchange for Ciclofilin having the right to receive future milestone payments.
From June 30, 2015 to June 30, 2016 Issuance of common stock, net Stock option exercise
from June 30, 2015 to March 31, 2016 Exercise of stock options Issuance of common stock, net
From June 30, 2015 to December 31, 2015 Exercise of stock options Issuance of common stock, net
from June 30, 2015 to September 30, 2015 Exercise of stock options
from June 30, 2014 to June 30, 2015 Issuance of series A preferred shares Issuance of series B preferred shares Restricted common shares issued in exchange of warrants Beneficial conversion feature accreted as a deemed dividend
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。